Dashboard
Manage Tickers

MBRX


()    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

moleculin-biotech-announces-enrollment-and-treatment-of-patients-in-investigator-initiated-phase-2-study-of-wp1066-with-radiation-therapy-in-glioblastoma
Moleculin Biotech Announces Enrollment And...
09/09/2024 12:18:04

moleculin-biotech-shares-are-trading-lower-after-the-company-announced-the-pricing-of-a-public-offering-for-247-million-shares-and-series-a-and-b-warrants-at-223-per-share
Moleculin Biotech shares are trading lower...
08/16/2024 12:10:46

moleculin-biotech-announces-pricing-of-public-offering-for-247m-shares-series-a-and-b-warrants-at-223-per-share
Moleculin Biotech Announces Pricing Of Pub...
08/16/2024 12:04:47

Warrants Exercisable Upon Shareholder Approval With Series A Expiring In 2 Years And Series B In 5 Years, Subject To Interim An...

moleculin-biotech-q2-eps-170-beats-231-estimate
Moleculin Biotech Q2 EPS $(1.70) Beats $(2...
08/14/2024 12:12:04

Moleculin Biotech (NASDAQ:MBRX) reported quarterly losses of $(1.70) per share which beat the analyst consensus estimate of $(2...

moleculin-announces-plans-for-miracle-adaptive-phase-3-clinical-trial-designed-for-possible-accelerated-approval-of-annamycin-in-combination-with-cytarabine-for-the-treatment-of-relapsed-or-refractory-aml
Moleculin Announces Plans For MIRACLE Adap...
08/01/2024 12:36:43

Based on an encouraging discussion in the End of Phase 1B/2 Meeting with FDA the Company plans to:Proceed with a pivotal, adapt...

moleculin-biotech-completes-end-of-phase-2-meeting-with-fda-for-annamycin-in-aml-as-both-first-line-therapy-and-for-subjects-who-are-refractory-to-or-relapsed-after-induction-therapy
Moleculin Biotech Completes End Of Phase 2...
07/10/2024 12:32:36

Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company ...

12-health-care-stocks-moving-in-fridays-pre-market-session
12 Health Care Stocks Moving In Friday's P...
06/14/2024 12:06:22

moleculin-reports-additional-preliminary-interim-data-from-aml-clinical-trial
Moleculin Reports Additional Preliminary I...
06/14/2024 12:05:40

– 89% of CRc's were subjects with "poor prognosis" cytogenetics and/or mutations – Current median durability of res...

moleculin-biotech-files-for-mixed-shelf-offering-of-up-to-200m
Moleculin Biotech Files For Mixed Shelf Of...
06/07/2024 21:18:19

 - SEC Filing

moleculin-commences-nih-funded-phase-2-clinical-trial-of-stat3-inhibitor-for-glioblastoma
Moleculin Commences NIH-Funded Phase 2 Cli...
05/15/2024 12:40:04

– Investigator-Initiated Phase 2 study is being conducted at Northwestern University in cooperation with Moleculin– Trial combi...

moleculin-biotech-q1-eps-202-beats-353-estimate
Moleculin Biotech Q1 EPS $(2.02) Beats $(3...
05/10/2024 21:09:42

Moleculin Biotech (NASDAQ:MBRX) reported quarterly losses of $(2.02) per share which beat the analyst consensus estimate of $(3...

moleculin-biotech-received-issue-notification-from-us-patent-and-trademark-office-for-us-patent-number-11980634-titled-method-of-reconstituting-liposomal-annamycin
Moleculin Biotech Received Issue Notificat...
05/09/2024 12:43:26

Patent, once issued, will provide composition protection through 2040, with potential for additional term extensionAnnamycin is...

moleculin-reports-higher-aml-complete-remission-rates-and-durability-with-additional-interim-subject-data
Moleculin Reports Higher AML Complete Remi...
05/07/2024 13:02:30

Annamycin in combination with Cytarabine (AnnAraC) achieves CRc rate of 62% (54% CR) in 1st and 2nd line AML subjects (N=13)Ful...

moleculin-announces-formation-of-scientific-advisory-board-to-support-development-of-annamycin
Moleculin Announces Formation Of Scientifi...
05/01/2024 13:01:27

12-health-care-stocks-moving-in-fridays-pre-market-session
12 Health Care Stocks Moving In Friday's P...
04/26/2024 12:06:32

european-medicines-agency-grants-orphan-drug-designation-for-moleculins-treatment-of-acute-myeloid-leukemia
European Medicines Agency Grants Orphan Dr...
04/18/2024 12:36:14

roth-mkm-maintains-buy-on-moleculin-biotech-maintains-40-price-target
Roth MKM Maintains Buy on Moleculin Biotec...
04/12/2024 16:24:03

Roth MKM analyst Jonathan Aschoff maintains Moleculin Biotech (NASDAQ:MBRX) with a Buy and maintains $40 price target.

moleculin-presents-data-for-anthracycline
Moleculin Presents Data For Anthracycline
04/10/2024 12:34:09

12-health-care-stocks-moving-in-mondays-after-market-session
12 Health Care Stocks Moving In Monday's A...
04/08/2024 20:31:20

moleculin-received-us-patent-issue-notification-for-annamycin-targeting-unmet-need-in-aml
Moleculin Received U.S. Patent Issue Notif...
03/27/2024 13:06:48

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION